Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab + Chemotherapy in Recurrent Ovarian Cancer
NCT03353831Phase 3Completed
- Sponsor
- AGO Research
- Start
- Sep 2018
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of atezolizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by AGO Research. Primary endpoints: Overall Survival up to 40 months and Progression-free Survival up to 40 months. Started Sep 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03353831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03353831.